S
7.30
-0.44 (-5.68%)
| Penutupan Terdahulu | 7.74 |
| Buka | 7.75 |
| Jumlah Dagangan | 14,204 |
| Purata Dagangan (3B) | 160,380 |
| Modal Pasaran | 21,561,782 |
| Harga / Jualan (P/S) | 1.80 |
| Harga / Buku (P/B) | 0.720 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 19 May 2025 - 23 May 2025 |
| Margin Keuntungan | -91.70% |
| Margin Operasi (TTM) | -2,193.89% |
| EPS Cair (TTM) | -3.80 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -37.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 4.53% |
| Nisbah Semasa (MRQ) | 5.92 |
| Aliran Tunai Operasi (OCF TTM) | -13.89 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -9.91 M |
| Pulangan Atas Aset (ROA TTM) | -18.51% |
| Pulangan Atas Ekuiti (ROE TTM) | -31.35% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menurun | Menurun |
| Biotechnology (Global) | Menurun | Menurun | |
| Stok | Sol-Gel Technologies Ltd. | Bercampur | Menurun |
AISkor Stockmoo
-0.5
| Konsensus Penganalisis | -2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | -0.50 |
|
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline consists of silica-based microencapsulation technology platform, and several generic product candidates across multiple indications. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 66.23% |
| % Dimiliki oleh Institusi | 24.29% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Caliber Wealth Management, Llc / Ks | 31 Mar 2025 | 1,300 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 23 May 2025 | Pengumuman | Sol-Gel Reports First Quarter 2025 Results |
| 01 May 2025 | Pengumuman | Sol-Gel Announces Reverse Share Split |
| 17 Apr 2025 | Pengumuman | Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S. |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |